Weiss Ratings restated their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG - Free Report) in a research note published on Wednesday morning,Weiss Ratings reports.
A number of other equities research analysts also recently weighed in on TXG. Canaccord Genuity Group reduced their price target on shares of 10x Genomics from $18.00 to $15.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Wall Street Zen upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Leerink Partnrs downgraded shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. Stephens restated an "overweight" rating and issued a $14.00 price target on shares of 10x Genomics in a research note on Thursday, May 15th. Finally, JPMorgan Chase & Co. reduced their price target on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $15.81.
Get Our Latest Stock Analysis on 10x Genomics
10x Genomics Trading Down 1.6%
10x Genomics stock traded down $0.17 during trading hours on Wednesday, reaching $10.41. 2,237,808 shares of the stock were exchanged, compared to its average volume of 2,553,935. The company has a market cap of $1.28 billion, a P/E ratio of -6.85 and a beta of 1.99. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $24.76. The stock has a 50 day moving average of $8.75 and a two-hundred day moving average of $11.53.
10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The firm had revenue of $154.88 million for the quarter, compared to the consensus estimate of $131.91 million. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The business's revenue for the quarter was down 2.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.50) earnings per share. On average, analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, insider Benjamin J. Hindson sold 7,485 shares of 10x Genomics stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total value of $62,125.50. Following the completion of the sale, the insider now owns 448,374 shares in the company, valued at $3,721,504.20. The trade was a 1.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Adam Taich sold 4,044 shares of 10x Genomics stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $33,565.20. Following the completion of the sale, the chief financial officer now owns 331,588 shares of the company's stock, valued at $2,752,180.40. This represents a 1.20% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,872 shares of company stock worth $173,238. 9.39% of the stock is currently owned by insiders.
Institutional Trading of 10x Genomics
Several hedge funds have recently modified their holdings of TXG. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics in the 4th quarter valued at $52,000. Entropy Technologies LP boosted its holdings in 10x Genomics by 285.6% during the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company's stock worth $540,000 after acquiring an additional 27,844 shares during the last quarter. Savant Capital LLC boosted its holdings in 10x Genomics by 69.3% during the 4th quarter. Savant Capital LLC now owns 40,247 shares of the company's stock worth $578,000 after acquiring an additional 16,480 shares during the last quarter. Blue Trust Inc. boosted its holdings in 10x Genomics by 86.5% during the 4th quarter. Blue Trust Inc. now owns 3,312 shares of the company's stock worth $48,000 after acquiring an additional 1,536 shares during the last quarter. Finally, Sanctuary Advisors LLC boosted its holdings in shares of 10x Genomics by 36.0% in the 4th quarter. Sanctuary Advisors LLC now owns 24,433 shares of the company's stock worth $368,000 after buying an additional 6,474 shares during the last quarter. Institutional investors own 84.68% of the company's stock.
10x Genomics Company Profile
(
Get Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Read More

Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.